Introduction
Osteonecrosis of the jaw (ONJ) represents a clinically important, potentially painful, and debilitating condition that can meaningfully affect the quality of life (QoL) of cancer patients. Since 2003, ONJ appeared as a bisphosphonate (BP)-related class effect, and the term bisphosphonate-related osteonecrosis of jaw (BRONJ) was used. Recent studies have shown that the new receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor denosumab can equally induce ONJ. Furthermore, ONJ cases have been reported after treatment including antiangiogenic agents and other 'targeted therapy', with and without BPs, in cancer patients. Consequently, the term medication-related osteonecrosis of jaw (MRONJ) has been recently introduced in medical literature.
As every year novel drugs with antiangiogenic properties and multi-target mechanisms are introduced in the anticancer therapeutic armamentarium, clinicians and patients have to give high attention to oral health problems during treatment with new agents, in order to distinguish between stomatitis, a very common side effect of most of these drugs, and potential signs of early MRONJ, with or without bone exposure.
Risk factors related to ONJ are known, but it does not exist as a complete picture. Radiotherapy of head and neck tumors, periodontal diseases, jawbone surgery, and edentulous zones or prosthesis have been reported as related with the development of ONJ. [1] Among the risk factors, it is also consideredthe systemic treatments, especially if prolonged, with BPs. [2] However, the concomitant dentoalveolar surgery and periodontal/dental diseases are the main risk factors.
Oral surgery (implantology and periapical surgery) increases the risk of ONJ, as well as concomitant imbalance of oral health (e.g. dental inflammation and dental abscesses). Finally, there are risks associated with tumor histology, age, and race. Multiple myeloma was most often associated with ONJ compared to other solid tumors [3] in first reports. Moreover, it is unknown what impact these drugs have on patients' oral-QoL, specifically in relation to any subclinical manifestations that may not be routinely identified during cancer therapy. Although it is not known whether the injuries caused by osteoclasts inhibiting agents are equal to those caused by antiangiogenetic agents, literature shows how the QoL is adversely affected by osteomyelitis of the jaw during BPs or denosumab treatment. The first empirical evidence that BP-associated ONJ significantly impairs QoL, with an increasing effect with stage severity was published in 2011. [4] ONJ adversely affects a wide range of oral health, and the magnitude of the negative QoL effects of ONJ is equivalent to other cancer treatment side effects that influence treatment decisions. [5, 6] By translating evidences emerging in studies of inhibitors of osteoclast activity, it could easily figure out how the QoL of patients with ONJ may be compromised by other agents, such as anti-vascular endothelial growth factor (VEGF), mammalian target of rapamycin (mTOR) inhibitors, and tyrosine kinase inhibitors (TKIs). VEGF is essential for bone repair mechanisms so the use of anti-VEGF drugs (both monoclonal antibodies and TKIs) could theoretically cause ONJ, even without concomitant use of BPs.
Even if rarely, a delayed or missed diagnosis of ONJ might exist in life-threatening or lethal disease (necrotizing fasciitis or neck cellulitis) [7] [8] [9] [10] : so, every effort to avoid delayed or missed diagnosis is warranted.
The first case report associating bevacizumab with the onset of ONJ was published in 2008 [11] ; subsequently, it was retrospectively analyzed for the data of safety on the use of bevacizumab in improving the clinical outcome of patients with breast cancer (ATHENA, AVADO, and RIBBON-1) [12] demonstrating that the concomitant use of bevacizumab plus intravenous BPs significantly increased the risk of ONJ compared with the use of bevacizumab or BP alone. The same mechanism that underlies the hypothetical pathogenesis of ONJ with the use of bevacizumab may be shifted to the administration of TKIs in particular with sunitinib in metastatic renal carcinoma and gastro intestinal stromal tumor (GIST). Wide use of sunitinib in clinical practice, especially in patients with localization of bone disease that require agents inhibiting osteoclast activity, led to the identification of patients who reported ONJ disease sites. [13] The population of patients with renal cancer was also analyzed for the use of inhibitors of mTOR, such as everolimus and temsirolimus. In fact, there were two published case reports [14, 15] in which, patients previously treated with BPs have reported ONJ. Further studies are needed to determine what is the role of the individual drugs, if there is a synergy or a trigger component. A diagnostic algorithm designed on the emerging evidence is necessary in order to identify high-risk patients, for which a preventive and coded approach is necessary. The proper stratification of patients' risk class could help in improving the decision-making and improving the patient's adherence to the treatments with a hypothetical consequent betterment of clinical outcome.
Definition of ONJ
The definition of ONJ is controversial, with evident consequences on clinical practice, trials and epidemiological studies. The most applied definition of ONJ is the one that was originally proposed by a Task Force of the American Association of Maxillofacial Surgeons (AAOMS) in 2006 and published in 2007, [16] based on presence of bone exposure lasting at least 8 weeks in patients treated with BPs and never treated with radiation on head and neck region. That definition was linked to a staging system based on the presence of clinical signs and symptoms, and it was also substantially approved by a Task Force of the American Society of Bone and Mineral Research (ASBMR). [17] In succeeding years, the term BRONJ entered largely in use in medical literature, also when the first cases of ONJ after treatment including antiangiogenic agents and denosumab began to be reported. [18, 19] In the same years, clinical practice and literature [20, 21] showed increasing evidence of symptomatic cases of BP-related jawbone alterations without frank bone exposure, therefore, questioning the ONJ definition.
In 2009, the AAOMS Task Force [22] did not modify the definition but added a 'stage 0' to classify cases with signs and symptoms of the jaws without bone exposure; the contradictory nature of that position paper was underlined by several authors and researchers calling for a new larger definition to include the non-exposed ONJ. [23] [24] [25] [26] [27] [28] [29] [30] Finally, in 2014, an AAOMS special committee released a third position paper [31] changing the term from BRONJ to medicationrelated ONJ (MRONJ) in order to include cases linked to the treatment with denosumab and those arising after antiangiogenic drugs and targeted therapies; the document enlarged the definition of disease to include cases with 'bone that can be probed through an intraoral or extraoral fistula in the maxillofacial region that has persisted for longer than 8 weeks' and confirmed the existence of a 'stage 0 category' for patients with signs and symptoms without bone exposure. On the other hand, an international task force recently confirms the ASBMR 2007 definition without the AAOMS 2009 and 2014 amends. [32, 33] These controversies on definition are clearly of paramount importance as a possible cause of incorrect estimation of ONJ incidence on clinical studies, as well as patient selection and follow-up duration, [34] and they might also induce under-diagnosing of ONJ cases in clinical practice. Furthermore, the purely clinical-based definition of ONJ is questioned by the emergent role of imaging studies. [35, 36] 3. ONJ related to drugs other than antiresorptives Between 2003 and 2008, the medical literature registered an explosion of Reports and Papers regarding ONJ related to BPs, the so-called BRONJ. [37] The etiology of BRONJ has not yet been completely elucidated [38, 39] ; it is probably of multifactorial origin, due to different possible mechanisms:
• osteoclast inhibition, consequent bone resorption arrest, and turnover disruption; • bone infection;
• the antiangiogenic effect of various BPs (such as zoledronic acid); • immune system modification;
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• a BP-related toxic effect on cells other than osteoclasts (i. e. soft tissue cells); and • other possible co-factors, such as microtrauma and vitamin D deficiency.
The number of biological and animal model data is growing, but currently there is no single phenomenon explaining the variety of ONJ, which has arisen after intravenous or oral BP treatment. [40] After bone remodeling alterations, the antiangiogenic activity of BPs has been suggested as one of the main determinants of the onset of ONJ [41, 42] ; the impact of VEGFR genetic polymorphism has also been investigated. [43] Further data have been obtained from studying the apoptosis of circulating endothelial cells following the treatment with BPs [44] and from several animal models. The role of tooth extraction or other alveolar trauma in the onset of ONJ is not entirely known although it may well be a possible trigger as well as a sentinel of pre-existing, underlying bone disease. The risk factors for BRONJ, classified as systemic or local, have been largely described. [40] Denosumab is a completely humanized monoclonal antibody, an inhibitor of RANKL (which is secreted by osteoblasts), acting as a bone turnover blocker. Consequently, and theoretically, denosumab-related ONJ disease could have characteristics unlike those of BRONJ. Further large-scale studies are required to ascertain whether denosumab-related ONJ cases do have a more favorable outcome after 'conservative' therapies (antibiotics and topic treatment) and/or drug suspension. [45] [46] [47] [48] Since 2008, a possible role of targeted therapies (i.e. antiangiogenic drugs), together with antiresorptives, in developing ONJ has been suggested and investigated. [19, 49, 50] The so-called anticancer 'targeted therapies' include very different classes of drugs, acting on several cellular signaling pathways, often with 'multi-target' mechanisms. The list of the drugs implicated in the development of ONJ is now increasing, and it will probably continue to do so in the future as several mechanisms are likely to be involved in ONJ, other than disrupting the bone remodeling process. For example, a toxic effect of drugs on soft tissue cells and the local immune system could add to the imbalance between bone resorption and bone formation, which seems the main factor in unraveling the development of BRONJ.
The ONJ-inducing capacity of innovative drugs, such as antiangiogenic and targeted therapies, can be inferred by the following two observations:
(1) The description of ONJ cases in patients treated with such drugs, having not received BPs (or denosumab). These cases serve as the main proof of the existence of ONJ as side effects. (2) An increase in cases of ONJ in populations of cancer patients undergoing treatment, which included BPs (or denosumab) and the studied drugs.
At this moment, data exist mainly about three agent classes capable of inducing MRONJ:
(i) drugs with main antiangiogenic mechanism (bevacizumab and aflibercept); (ii) small molecule TKIs (sunitinib, sorafenib, and cabozantinib);
(iii) inhibitors of mammalian target of rapamycin (mTOR inhibitors).
The main mechanism of ONJ induced by these novel drugs appears in the antiangiogenic effect, already claimed for BPs (i. e. zoledronic acid), but other mechanisms cannot be excluded.
Association of antingiogenic drugs and antiresorptive agents (BPs and denosumab): general considerations
The first data regarding ONJ cases in patients receiving bevacizumab, the first-developed, and most administered antiangiogenic agent appeared in 2008. Bevacizumab has been approved for several antitumor treatments (including the therapy of colorectal cancer, renal cancer, lung cancer, breast cancer, ovarian cancer, and glioblastoma) and for macular degeneration. The first two reports regarding the association of ONJ with bevacizumab both derived from the Memorial Sloan Kettering Cancer Center (MSKCC) in New York. Estilo et al. [11] published a report in the Journal of Clinical Oncology regarding two cases of osteonecrosis of the jawbone, in one patient with breast cancer and in one patient with glioblastoma, both of whom had been treated with bevacizumab with no history of BP therapy. At the 2008 annual ASCO meeting, McArthur et al. [51] presented an abstract with cases of ONJ in patients treated at MSKCC only with BPs (72 out of 6561, 1.1%) or BPs and bevacizumab (8 out of 409, 2.0%). At the subsequent conference presentation, the data were different, also including ONJ cases that had been observed after treatment only with bevacizumab (probably those reported in the article by Estilo et al.): 76 out of 6534 patients with ONJ had been treated only with BPs, 9 out of 409 had been treated with bevacizumab and BPs, and 2 out of 1711 had only been treated with bevacizumab without BPs.
Suggestive data for an increased ONJ risk have also come from experimental trials in prostate cancer patients by Aragon-Ching et al. [52] [53] [54] with very high incidence of ONJ (up to 17%) following treatment with zoledronic acid, bevacizumab, and thalidomide.
In subsequent years, reports of ONJ cases after treatment with sunitinib have appeared in the medical literature. [55] [56] [57] [58] [59] [60] [61] [62] In a limited cohort, Christodolou et al. observed 5 cases of ONJ among 116 patients who had been receiving BPs from 2007 to 2008, of which 4 had received bevacizumab or sunitinib, [10] thus suggesting an increased risk of ONJ, which is derived from an association of BPs and innovative agents.
The European Medical Agency (EMA) released alerts in 2010 regarding the risks of ONJ after treatment including bevacizumab or sunitinib. [63] Referring to the letters from doctors outlining these alerts, the manufacturers of the drugs declared the following frequency of reported ONJ cases worldwide: 55 out of 800,000 patients treated with bevacizumab, and 27 cases of ONJ out of 101,400 patients receiving sunitinib, most of them also received BPs.
Three large pivotal trials have compared denosumab and zoledronic acid in patients with bone metastases of advanced solid tumors and the results were published separately and on an integrated form with one paper specifically dedicated to ONJ. [45, 64] As previously noted, [65] there were 14 cases of ONJ in the three trials out of 464 patients (3.0%) who had been treated with an antiresorptive agent (zoledronic acid or denosumab) and antiangiogenic agents versus 75 cases of ONJ cases out of 5259 patients (1.4%) receiving zoledronic acid or denosumab and no antiangiogenic agents. This, therefore, suggests a possible higher risk of ONJ from a combination of antiresorptive and antiangiogenic agents. Up to 35% of advanced renal cell cancer (RCC) patients develop bone metastases, and they are often treated with BPs, mainly zoledronic acid. BRONJ was rarely reported in RCC patients in the first few years of observing ONJ (2003) (2004) (2005) (2006) ; this was probably due to a short life extension and expectancy and, indeed, there was no mention of RCC patients in the first systematic review reporting ONJ cases published between 2003 and 2005. [66] Few ONJ cases in RCC patients were described after that period. [67] Recently, treatment and prognosis of most metastatic RCC patients have improved, thanks to availability of seven innovative agents: an anti-VEGF monoclonal antibody (bevacizumab), four TKIs, i.e. sorafenib, sunitinib, pazopanib, and axitinib, and two mTOR inhibitors, i.e. temsirolimus and everolimus. Consequently, bone metastatic RCC patients routinely receive targeted therapy as first and further treatment lines, with life expectancy of metastatic RCC patients having almost tripled, leading to a longer exposure to BPs, and thus an increased risk of ONJ. Recent reports have suggested a relatively high ONJ risk in RCC patients after a combination of BPs (mostly zoledronic acid) and antiangiogenic agents (mostly sunitinib). [13, [67] [68] [69] Bozas and co-workers [68] identified 5 ONJ cases out of 21 RCC patients, who were treated with a combination of BPs and antiangiogenic drugs (23.8%), with a cumulative hazard ratio for ONJ of 5% (95% confidence interval [CI], 0-10%) and 36% (95% CI, 23-49%) after 12 and 24 months of treatment with zoledronate, respectively. The authors' conclusion suggests a potential synergy of sunitinib and zoledronic acid in inducing ONJ. In another retrospective study, Beuselinck et al. [69] found that the incidence of ONJ among RCC patients increased up to 10% when BP and TKIs were administered in combination, with a projected incidence of 17% of ONJ over 24 months. The authors also hypothesized a possible underestimation of the incidence of ONJ due to the limited survival of patients in the cohort and the short duration of treatment with BP for most patients. A Danish study [13] registered a 29% incidence of ONJ in RCC patients treated with zoledronic acid and targeted therapy (mainly sunitinib), but the rate decreased to 11% when oral screening before commencing treatment was recommended. Italian authors collected 44 cases of ONJ with different combinations of BP and targeted agents. [67] Further literature data seem to strengthen the role of the association of antiresorptives and antiangiogenics in determining ONJ in RCC patients.
First, in the three aforementioned denosumab versus zoledronic acid trials [45, 64] of the 89 total adjudicated ONJ patients (treated either with zoledronic acid or denosumab), there were 6 RCC patients (6.7%) out of a total number of enrolled RCC patients of 155. This 6/155 (3.9%) ONJ frequency in RCC patients is more than twice as high if compared with the entire patient population (1.6%). [65] Unfortunately, whether those six RCC patients developing ONJ had received antiangiogenic agents or which bone antiresorptive agent had been administered was not discussed in the quoted reports.
Second and in contrast with the initial ONJ reports, the ONJ case series published more recently, included RCC patients in a significant measure, with a frequency ranging from 1% to 4.5% of all observed ONJ cases. [67, 70] 
VEGF-mediated antiangiogenic drugs in solid tumors
Drugs acting against the angiogenesis involving VEGF include bevacizumab and aflibercept.
Bevacizumab
Bevacizumab is a monoclonal antibody linking to the angiogenesis growth factor VEGF-A; it was approved for several antitumor treatments (including treatment of colorectal, renal, lung, breast, ovarian, and cervix cancer; glioblastoma), and for macular degeneration treatment. ONJ cases were published in patients receiving bevacizumab since 2008, both on bevacizumab alone and together with BPs (see earlier). ONJ cases after bevacizumab alone were observed in colorectal, breast, lung, parotid gland, and renal cancer patients, and revealed differentiated clinical history and outcome. [12, 18, [71] [72] [73] [74] [75] [76] Furthermore, one case was observed after intravitreous bevacizumab. [77] Some other published cases are notable: one pancreatic cancer patient showed ONJ during treatment with bevacizumab and sorafenib [78] and one renal cell cancer patient had received bevacizumab plus temsirolimus [79] ; another renal cell cancer patient developed ONJ during bevacizumab treatment, after previous treatments with sunitinib and temsirolimus. [80] To note, one glioblastoma patient developed a severe complication after a single bevacizumab infusion [81] compatible with complicated ONJ. Besides case reports, few data are available about frequency of bevacizumabrelated ONJ. We have already reported the initial experience from Memorial Sloan Kettering Cancer Center. [51] In 2010, a retrospective study on breast cancer patients revealed a very low risk after bevacizumab alone (0.3-04%) in comparison with the combination of bevacizumab and BPs (0.9-2.4% range) within a large trial population [12] However, only ONJ cases with frank bone exposure were registered in that analysis, and median follow-up of groups ranged only between 10 and 19 months. Were ONJ cases in bevacizumab-treated patients somewhat different from BRONJ cases? In a single center experience report, Ngamphaiboon et al.
[82] compared 7 ONJ cases observed after BPs and bevacizumab treatment and 20 cases after BPs without bevacizumab, all observed at the Roswell Park Cancer Institute, without relevant differences. Lescaille et al. [83] on the contrary found in their 42 ONJ case population that bevacizumab was associated to earlier onset, higher risk of spontaneous developing (without trigger) and higher number of jaw lesions.
Aflibercept
Aflibercept is another agent potentially capable of determining ONJ. Aflibercept, the so-called 'VEGF trap', is an antiangiogenic agent with mechanism of action different from that of bevacizumab, being a soluble decoy VEGF receptor.
Aflibercept has been approved for treatment of advanced colorectal cancer and has been largely evaluated as treatment of other cancer types. ONJ cases in patients receiving aflibercept are present in an integrated safety database reported by North American and European agencies in 2012 [84] : out of six ONJ cases among aflibercept-treated patients three patients also received BPs. Two ONJ cases were observed within the pivotal VELOUR (VEGF-trap with irinotecan in colorectal cancer after failure of oxaliplatin) trial, [85] of which only one case of treatment with BPs was found. [84] Another ONJ case was observed in an exploratory trial of aflibercept on melanoma patients, but the patient was also irradiated to head and neck area. [86] One more case has been recently reported. [87] As aflibercept has been and will be probably more largely administered to colon cancer patients, a large population of patients partially pretreated with bevacizumab and more cases are reasonably to be expected.
TKIs
TKIs are drugs with differentiated effects (including antiangiogenic ones) [88] : they block tumor growth and inhibit angiogenesis through multi-target mechanisms. A large number of TKIs have been registered as active drugs and authorized for clinical practice, or are under evaluation in phase II and phase III trials. At our best knowledge, no cases of ONJ have been published among patients participating to trials that conducted to registration of approved agents, such as sunitinib, sorafenib, pazopanib, axitinib, gefitinib, erlotinib, crizotinib, ceritinib, imatinib, dabrafenib, dasatinib, regorafenib, etc., in a series of cancer types (renal cell cancer, soft-tissue sarcoma, lung cancer, pancreatic neoplasms, gastrointestinal stromal tumors (GISTs), hepatocellular cancer, melanoma, thyroid cancer, colon cancer, etc.). Nevertheless, we have to remind that no cases of ONJ had been initially reported even in pivotal papers that conducted large introduction in clinics of BPs determining BRONJ (alendronate, risedronate, ibandronate, pamidronate, zoledronic acid) in 1990s and in the beginning of this century; and neither ONJ cases were present in reports of first trials with bevacizumab and sunitinib. Consequently, we should wait for observation in large confirmatory studies, and above all in clinical practice population out of clinical trials (i.e. observational studies and drug surveillance system reports), with adequately long follow-up time, before excluding capacity of TKIs other than sunitinib to determine ONJ without antiresorpive agents.
Sunitinib
Most of the data available for TKI-related ONJ cases are linked to sunitinib, a drug-inducing stomatitis and dental side effect in a large proportion of patients. [89] Besides initial reports of patients also treated with BPs, [10, 55, 56, 58, 62, 90] sunitinib appeared as the only agent administered in some RCC patients suffering of ONJ [59] [60] [61] Furthermore, sunitinib was associated to BPs in numerous ONJ cases in RCC population, [67] with an incidence higher than expected when a denominator was reported. [13, 57, 69] However, Smidt-Hansen reported the possibility of decreasing the ONJ risk after adopting preventive measures (as well as recommended in general BP-treated population).
Other TKIs
Data about sorafenib-related ONJ risk are scarce, and are absent for those about possible role of pazopanib and axitinib. Sorafenib treatment was present, as only targeted therapy or in sequence with others, in the treatment history of RCC patients also receiving BPs. [67, 69] One case report has been published about MRONJ observed in a patient with medullary thyroid cancer treated with cabozantinib without BP treatment history [91] ; three ONJ cases had been reported in the original pivotal trial by Elisei et al., [92] but data about eventual BP treatment are missing.
mTOR inhibitors
Inhibitors of mTOR pathway are largely administered as immunosuppressive agents as well as anticancer drugs. [93] Inhibitors of mTOR (everolimus and temsirolimus) are agents approved for anticancer treatment (renal cell cancer, breast cancer, and pancreatic neuroendocrine tumors) and prevention of solid organ rejection. As mTOR signaling is linked to the VEGF pathway, ONJ cases could be expected after treatment with those drugs.
Temsirolimus
Temsirolimus is approved for RCC; one case of ONJ in an RCC patient never treated with BPs has been observed after therapy with temsirolimus alone. [67, 94] Other two cases were observed during treatment with sunitinib and temsirolimus [62] and bevacizumab and temsirolimus. [79] One patient developed ONJ during treatment with ridaforolimus, an experimental agent, and pamidronate. [67] 
Everolimus
Everolimus is an mTOR inhibitor experimented in several cancer types and some rare diseases. [95] Everolimus is administered for several years for advanced renal cell cancer treatment: sparse cases of ONJ were reported in literature after treatment with everolimus together with BPs in RCC patients. [13, 14, 67, 96] Another case has been described after 3-year treatment with everolimus in a medullary thyroid cancer previously pretreated many years before with zoledronic acid. [15] Everolimus has been more recently studied in advanced breast cancer to revert endocrine resistance and obtained registration in association with exemestane, an endocrine agent. In the pivotal BOLERO-2 trial, [97, 98] ONJ has been observed in 2 out of 482 patients in the experimental (everolimus-exemestane) arm and 1 out 238 in the control (exemestane alone) arm, with one of the three pretreated with BPs, as reported by Gnant et al. in a corollary paper [99] ; however, no ONJ case was linked to the trial treatment by the local investigator. Finally, no ONJ cases have been reported in other trials with everolimus, but there was a notable heterogeneity in reporting side effects involving oral cavity, where 'stomatitis' (the most common side effect of everolimus) also included gingival swelling and jaw pain.
[100] Furthermore, in one everolimus trial, a 3% incidence of unexpected 'jaw pain' was classified among 'musculoskeletal and connective tissue disorders'.
[100] As reported by Aapro et al. [101] about breast cancer patients receiving everolimus, 'in theory, ONJ is part of the differential diagnosis at the presentation of a stomatitis event. Although the denuded bone area is easily distinguished from superficial mucosal lesions on the gum, preliminary symptoms, such as pain are observed in both clinical conditions'. Therefore, in consideration of possible cases of ONJ without frank bone exposure, further careful observation data about oral side effect in patients receiving everolimus (with/without BPs or denosumab) are recommended to avoid ONJ late or missed diagnosis.
Antiangiogenic drugs in myeloma
Thalidomide and analogs (lenalidomide and pomalidomide) have been largely adopted in the treatment of myeloma patients, a population largely receiving BPs and consequently at risk of BRONJ. Thalidomide and analogs have antiangiogenesis effect with not completely known mechanism, and consequently they might increase ONJ risk in myeloma patients; however, in spite of largely treated populations on trials, in practice there is no sufficient data to confirm or deny this hypothesis. [40] 
Other drugs
Very recently, a case of ONJ was observed in a melanoma patient receiving immunotherapy with ipilimumab at the Memorial Sloan Kettering Cancer Center in New York [102] ; no history of BP, denosumab, or antiangiogenic treatment was present. The ONJ case shortly resolved after antibiotic therapy and removal of bone sequestrum.
Specific characteristics of ONJ after antiangiogenic and other non-antiresorptive drugs
Further data are needed about the possibility that ONJ related to antiangiogenic agents show predominantly a clinical history different from that -already heterogeneous -of BRONJ: some papers reported about consecutive episodes of painful jaw infections, [56] with self-limiting history after antibiotic treatment and drug suspension [73] and without bone exposure or with limited exposure in time and in largeness. Imaging studies (particularly by computed tomography (CT) or bone scan scintigraphy) in case of symptomatic oral health discomfort in cancer patients receiving antiangiogenic and targeted therapies should be of great importance, as a large part of ONJ cases might escape the classical definition (requiring 8-week lasting bone exposure). Imaging studies of ONJ cases related to targeted therapies in comparison to those of BRONJ and denosumab-related ONJ cases are lacking at this moment.
Conclusion
As every year novel drugs with antiangiogenic properties and multi-target mechanisms are introduced in the anticancer therapeutic armamentarium, clinicians and patients have to give high attention to oral health problems during treatment with new agents, in order to distinguish between stomatitis, a very common side effect of most of these drugs, and potential signs of early ONJ, with or without bone exposure. As 20-30% of ONJ cases escape the classical definition (requiring 8-week lasting bone exposure), [24, 35, 36] great attention should be paid to imaging studies (particularly by CT or bone scan scintigraphy) in order to avoid underestimation of MRONJ.
Expert opinion
Some key-questions are consequently in front of clinical oncologists and other caregivers.
(1) How many patients suffer or will suffer ONJ after antiangiogenic agents, with or without concomitant administration ofBPs or denosumab?
We do not know exactly the burden of this new phenomenon. Safety surveillance systems will be helpful and should report case numbers likely higher than those extracted by literature reports. Unfortunately, propensity of physicians to register adverse drug reactions is far to be optimal. [103] Obviously, prospective collection and registration of data could be of even higher value, even if not uniformly applicable. [30] Furthermore, any data are to be interpreted with caution due to difficult adjudication of the adverse drug reaction to one drug or to another in cancer patients often receiving a large number of drugs simultaneously or in sequence.
For example, in Italy a large number of ONJ cases (several thousands) have been observed, and Italian physicians and dentists had contributed largely to knowledge and awareness of the disease with conferences, papers, and publications, [104] but only a minority of cases has been notified to the Italian Safety Drug Agency (AIFA). In march 2015, only 1513 cases of ONJ related to bisphosphonates in 10 years had been reported to AIFA; at that time, the AIFA database also contained 27 cases of ONJ related to denosumab, 16 related to bevacizumab, 20 to sunitinib, and 1 to sorafenib (AIFA, personal communication). This phenomenon of under-reporting is observed in other industrialized countries. [70, 105] Finally, available data relating to ONJ in patients treated with innovative anticancer drugs are scarce but on the increase. There is a high risk of underestimation due to a lack of awareness, and restrictive or inadequate diagnostic criteria, together with the need to improve the defining of any distinguished feature in the diagnosis, prevention, and therapy of ONJ, as associated with nonantiresorptive agents.
(2) Who are the patients at higher risk of ONJ during or after treatment including antiangiogenic agents?
From an epidemiological point of view, till now breast and prostate cancer patients with bone metastases and myeloma patients have been the main ONJ populations due to more frequent and more prolonged BP and denosumab treatments. With reference to antiangiogenic treatments, renal cell cancer patients were one of the first at-risk populations due to enlarged adoption of targeted therapies, alone or with BPs, [67] but the extension of use of aforementioned drugs in some more patient populations could give higher probability of ONJ onset. It is the case of patients suffering colon cancer (receiving bevacizumab, aflibercept, and other antiangiogenic drugs), lung cancer (bevacizumab, TKIs), and ovarian cancer (in future largely treated with bevacizumab). Furthermore, availability of inclusion of patients in several trials or extended access programs with novel drugs or treatment protocols could enlarge the risk; it is not infrequent that a single patient could receive more biological agents in sequence, on and off-label, especially if achieved survival is longer than usual. It is reasonable that longer drug(s) treatment duration and longer survival are elements associated with higher ONJ rates. With respect to the clinical features, in our opinion there is no definitive answer yet for a series of reasons. First, it is difficult to attribute the adverse drug reaction (ONJ) exclusively to one drug or to another in cancer patients often receiving a large number of drugs simultaneously or in sequence. After observing cases of ONJ where patients were treated with antiangiogenic agents with concomitant or previous antiresorptive drugs, the clinical findings have been quite similar to those in patients taking BPs even after shorter treatment durations and/or lower cumulative dosages, hypothesizing a precipitating role for antiangiogenic agents: for example, Lescaille et al. reported the onset of ONJ after a median of 12.4 months of bevacizumab and zoledronate in comparison with a median 22.9 months in patients who received only zoledronate. [83] Description of ONJ literature cases after antiangiogenic agents without history of antiresorptive drugs is variable; the ONJ clinical history (particularly presence or not of bone exposure, duration of exposure, and shortterm improvement or worsening) could be probably related to drug effects on soft tissues (gingival) and influenced by drug administration schedule. A peculiarity of these new classes of drugs, different from BPs, is their pharmacodynamics (without bone accumulation) and shorter half-life (e.g. around 40-50 days for bevacizumab; 7 days for sunitinib, aflibercept, everolimus); as a consequence, it is possible, in case of ONJ onset with accordance between oncologist and dental care specialist, to plan their suspension in view of a resolution of ONJ event.
(4) How to label this aforementioned ONJ form and is it hard to diagnose it?
Since 2003, ONJ appeared as a BP-related class effect, and the term BRONJ was widespread. Recent studies have shown that denosumab is also capable of inducing ONJ as well as antiangiogenic agents and other 'targeted therapies', consequently, the core 'ONJ' is once again largely used alone; alternatively, the term MRONJ has been recently introduced.
[31] With respect to the diagnostic work-up, the main problem is the possible under-diagnosing of ONJ cases without bone exposure. A recent multicenter study [24] has demonstrated that the use of the traditional AAOMS [16, 37] and ASBMR case definition [17] induces clinicians up to a quarter of undiagnosed BRONJ cases. These cases regard those patients who do not have any bony exposure but they do have unexplained pain in the jaws, fistula, loose teeth, swelling, and occasional pathological mandibular fracture. Thus, in order to avoid any underestimation of ONJ in general, care should be taken with respect to the definition adopted, and to the use of the imaging studies (particularly by CT or bone scan scintigraphy) of symptomatic oral health discomfort in cancer patients, who are already receiving antiangiogenic and targeted therapies in combination with antiresorptives or alone. In 2014, the AAOMS [31] admitted the existence of a non-exposed ONJ disease, conceding for the first time the definition of ONJ at least for cases without bone exposition and with bone probing via sinus/fistula tracts, but the task force did not change the old statement on staging (including the description of a 'stage 0' conflicting with the definition). Notwithstanding this development, many studies in this field still continue, unreasonably (the authors contend), to adopt the 2009 AAOMS definition. [37] In the report by Saad et al. [45] of the cumulative data of the three denosumab versus zoledronate trials, 89/ 5723 ONJ cases (1.5%) were adjudicated according to strict AAOMS criteria, but 276/5723 (4.8%) cases were suspected for ONJ signs or symptoms ('potential ONJ'): it is natural to doubt about possible missed ONJ diagnosis. On the other hand, the AAOMS definition of ONJ has been recently found to be 'unfit for purpose' in the spontaneous reporting database: by authors its use should be avoided, leading to the exclusion of over 70% of cases from the database. [106] An effective improvement in the ONJ staging was demonstrated by CT. [28, 30] Finally, it appears particularly challenging for the determination of early imaging (CT) signs of bone alteration, already described in BP-related ONJ [24, 36] ; moreover, this kind of imaging could be potentially valuable not only in order to facilitate recognition of ONJ without bone exposure but also to make easier the differential diagnosis between ONJ and drug-related long-lasting stomatitis, a possible problem after some drug treatment (e.g. everolimus). [101] Scintigraphy bone scan and positron emission tomography could be of value in differential diagnosis, but their cost-effectiveness (if not already made due to cancer disease staging) seems not warranted.
(5) What dental preventive measures could be taken in patients receiving antiangiogenic and targeted therapies?
As of now, there is not a validated user guide for these classes of drugs. But, it is believed that the major local risk factors remain, at this moment, the same dental history features as already known for patients receiving BPs and denosumab: i.e. tooth extraction and alveolar surgery, implants, illfitting dentures, and poor oral health. Hence, in general, the preventive protocols already adopted for the antiresorptive agents [40] might be used for these new drugs. These agents share a characteristic with denosumab, that is the option of the drug holiday in case of surgical dental procedures. The aim of this is to reduce the risk of an ONJ event after a tooth extraction, or endodontic surgery, or prosthodontic surgery.
However, the authors wish to specify that there is no robust literature relating to this topic; on the basis of the half-life of the molecules involved, it could be useful to adopt a drug holiday scheme for cancer patients. The authors suggest the drug holiday time as indicated in Table 1 .
In summary, the authors believe that ONJ is a clinically important, potentially painful, and debilitating condition, which can significantly affect the QoL of cancer patients. New patient populations are at risk of ONJ. The list of nonantiresorptive drugs, which are implicated in the development of ONJ, is growing and will probably continue to do so as several mechanisms are likely to be involved in ONJ, other than those disrupting the bone remodeling process. Moreover, the clinical aspects and especially the prognosis of ONJ associated with these new drugs seem to be unlike those used in BRONJ. Accordingly, recommendations for diagnosis, prevention, and treatment, which have already been developed and currently in use for BRONJ, should be adopted, but critically and cautiously, basing treatment on an individual risk assessment. Due to all these, a higher awareness of physicians (including oncologists and pathologists), dentists, nurses, and patients is the main way to obtain more information about drug-related ONJ, so that adequate measures could be adopted to minimize this potentially severe adverse drug reaction. 
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